Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Cost of Revenue (Sales)?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Cost of Revenue (Sales) is 
$586.3M (1Y +22.0% )

ALXN Stock Price & Cost of Revenue (Sales)

Cost of Revenue (Sales) for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Cost of Revenue (Sales)

chevron_right 2021 $152.2M +760x *
( +27.9% / year avg)
chevron_left 1995 -$200.0 T
vertical_align_top Peak $515.6M +860x *
vertical_align_bottom Bottom -$600.0 T
arrow_drop_up # Up Years 13 13 of 27
years up.
arrow_drop_down # Down Years 6
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -0.06x the rate relative to it's cost of revenue (sales) over the same period.
  • If ALXN grows it's stock at the same rate as it's cost of revenue (sales) (+27.9%/year) , it's stock price will grow +1,171% and hit $1273.55 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 13 years (0%) it's cost of revenue (sales) were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Cost of Revenue (Sales) Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Cost of Revenue (Sales) YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $152 -70.5% - -
    4/1/2020 $515 36.8% - -
    4/1/2019 $377 -10.6% - -
    4/1/2018 $421 11.8% - -
    4/1/2017 $377 112.9% - -
    4/1/2016 $177 -21.2% - -
    4/1/2015 $224 27.8% - -
    4/1/2014 $175 66.4% - -
    4/1/2013 $105 -13.2% - -
    4/1/2012 $121 44.1% - -
    4/1/2011 $84 48.1% - -
    4/1/2010 $57 46.5% - -
    4/1/2009 $38 56.3% - -
    4/1/2008 $24 654.5% - -
    4/1/2007 $3 - - -
    4/1/2006 $0 - - -
    4/1/2005 $0 - - -
    4/1/2004 $0 - - -
    4/1/2003 $0 - - -
    4/1/2002 $0 - - -
    4/1/2001 $0 - - -
    4/1/2000 $0 - - -
    4/1/1999 $0 - - -
    4/1/1998 $0 -100.0% - -
    4/1/1997 $0 -33.3% - -
    4/1/1996 $0 200.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • The cost of revenue is the total cost incurred to obtain a sale and the cost of the goods or services sold. Thus, the cost of revenue is more than the traditional cost of goods sold concept, since it includes those specific selling and marketing activities associated with a sale. The following are all considered part of the cost of revenue:

    For more detailed definitions, please see Investopedia.